Good morning: Has Astrazeneca reached its nadir? The drugs giant has posted first quarter results this morning. There is a promise of jam tomorrow — “we anticipate the significant progress of the pipeline to continue” — but little else. Analysts at Deutsche Bank argued this month that these results would mark the nadir for the group, forecasting a return to growth before the end of the financial year. Pascal Soriot, the embattled chief executive, must hope they are right.

Source: The Times April 27, 2017 08:15 UTC